Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
about
T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian childrenInduction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenSafety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trialPhase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children.Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.Approaching the target: the path towards an effective malaria vaccine.Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic regionShort report: elevated levels of alanine aminotransferase and hepatitis A in the context of a pediatric malaria vaccine trial in a village in Mali.AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.
P2860
Q28740701-62250EEC-25C6-4049-9ED1-D056E0638C6DQ28741242-90CBCEDA-F31C-4187-9BF3-2472960C0D3BQ28744573-9E8DB730-F8E7-40EF-B53D-14C0D9909151Q28748565-243823AB-2740-4EA4-8156-7D5638DCFD59Q33319552-48FBE330-AC38-414C-8A00-FC4E6B2184E5Q33489512-8A749F1F-DFFC-40B2-AD6D-5E406C35DE54Q33508797-C5DBB9CD-DE51-4660-B55F-D8490294AF8EQ33512921-72091B3F-149F-4F45-B0B8-7D4F1DCCBBD4Q34546220-C193C7C1-271D-4968-A902-67F709C149B1Q35924716-FB12B4AD-1429-4126-B48F-416636D258EFQ36568190-DBD0A2BD-FF34-40CB-A187-E8950D007A48Q37019155-1BE47A92-0975-47BE-99AA-512CF41B849CQ37144187-4CCA12EF-13BF-42EC-B555-8419468847A3Q37355917-AC88EB8E-1019-47D1-9593-80758AC757B7
P2860
Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Safety and immunogenicity of t ...... ildren aged 1-4 in Mozambique.
@en
type
label
Safety and immunogenicity of t ...... ildren aged 1-4 in Mozambique.
@en
prefLabel
Safety and immunogenicity of t ...... ildren aged 1-4 in Mozambique.
@en
P2093
P2860
P1476
Safety and immunogenicity of t ...... ildren aged 1-4 in Mozambique.
@en
P2093
Bevilacqua C
Dubovsky F
Guinovart C
Heppner DG
P2860
P356
10.1111/J.1365-3156.2006.01754.X
P577
2007-01-01T00:00:00Z